Pink Sheet reporter and editors discuss the issues and concerns raised during a major generic industry conference (:42), former FDA Commissioner Scott Gottlieb’s views on what a second Trump term as president would mean for the agency (13:54), and congressional hearings on FDA foreign manufacturing facility inspections and drug shortages (23:51).

More On These Topics From The Pink Sheet

‘We Did Too Good Of A Job’ On Lowering Prices: Sandoz’s Haruvi Discusses Generic Sustainability: https://pink.citeline.com/PS149745/We-Did-Too-Good-Of-A-Job-On-Lowering-Prices-Sandozs-Haruvi-Discusses-Generic-Sustainability

Blue Shield Of California’s Pharmacy Benefit Overhaul Could Still See Boost From Transparency Legislation: https://pink.citeline.com/PS149751/Blue-Shield-Of-Californias-Pharmacy-Benefit-Overhaul-Could-Still-See-Boost-From-Transparency-Legislation

Gottlieb: FDA Would Be Subject To More White House Control Under A Second Trump Term: https://pink.citeline.com/PS149737/Gottlieb-FDA-Would-Be-Subject-To-More-White-House-Control-Under-A-Second-Trump-Term

Congress Explores Plans For Catching Up On US FDA Foreign Inspections: https://pink.citeline.com/PS149744/Congress-Explores-Plans-For-Catching-Up-On-US-FDA-Foreign-Inspections

Environmental Regulations May Create Barriers To Onshoring More Rx Manufacturing: https://pink.citeline.com/PS149749/Environmental-Regulations-May-Create-Barriers-To-Onshoring-More-Rx-Manufacturing